145 related articles for article (PubMed ID: 1780686)
21. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies.
Solakidi S; Dessypris A; Stathopoulos GP; Androulakis G; Sekeris CE
Clin Biochem; 2004 Jan; 37(1):56-60. PubMed ID: 14675563
[TBL] [Abstract][Full Text] [Related]
22. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening.
Järvisalo J; Hakama M; Knekt P; Stenman UH; Leino A; Teppo L; Maatela J; Aromaa A
Cancer; 1993 Mar; 71(6):1982-8. PubMed ID: 8443749
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of tumor-associated trypsin inhibitor (TATI) in women with benign and malignant gynecological disease.
Inaudi P; Petrilli S; De Leo V; Bernabei A; Pasqui L; D'Antona N
Scand J Clin Lab Invest Suppl; 1991; 207():11-3. PubMed ID: 1780683
[TBL] [Abstract][Full Text] [Related]
24. Tumor-associated trypsin inhibitor (TATI) in bone diseases.
Rapellino M; Pecchio F; Broggi S; Baldi C; Ricardi G; Libertucci D
Scand J Clin Lab Invest Suppl; 1991; 207():65-6. PubMed ID: 1780696
[TBL] [Abstract][Full Text] [Related]
25. Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer.
Kasurinen A; Laitinen A; Kokkola A; Stenman UH; Böckelman C; Haglund C
Acta Oncol; 2020 Jun; 59(6):681-688. PubMed ID: 32124669
[No Abstract] [Full Text] [Related]
26. Biology and function of tumor-associated trypsin inhibitor, TATI.
Stenman UH; Koivunen E; Itkonen O
Scand J Clin Lab Invest Suppl; 1991; 207():5-9. PubMed ID: 1780691
[TBL] [Abstract][Full Text] [Related]
27. Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer.
Kelloniemi E; Rintala E; Finne P; Stenman UH;
Urology; 2003 Aug; 62(2):249-53. PubMed ID: 12893328
[TBL] [Abstract][Full Text] [Related]
28. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
29. Tumor-associated trypsin inhibitor in patients with chronic pancreatic diseases.
Plebani M; Basso D; Fabris C; Meggiato T; Del Favero G; Panozzo MP; Fogar P; Faggian D; Angonese C; Burlina A
Klin Wochenschr; 1989 Oct; 67(20):1029-32. PubMed ID: 2586008
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer.
Gao Y; Wang J; Zhou Y; Sheng S; Qian SY; Huo X
Sci Rep; 2018 Feb; 8(1):2732. PubMed ID: 29426902
[TBL] [Abstract][Full Text] [Related]
31. Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases.
Torre GC; Rembado R; Barbetti V; Vigliercio GP; Foglia M; Calabrese A; Corongiu F
Scand J Clin Lab Invest Suppl; 1991; 207():15-8. PubMed ID: 1780684
[TBL] [Abstract][Full Text] [Related]
32. Serum TATI levels and clinical correlation in tumors of the head and neck.
Rayo JI; Garcia-Talavera JR; Martin M; Muñoz A; Del Cañizo A
Scand J Clin Lab Invest Suppl; 1991; 207():33-5. PubMed ID: 1780687
[TBL] [Abstract][Full Text] [Related]
33. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of CEA, CA 19-9, CA-50, CA-195, and TATI with special reference to pancreatic disorders.
Masson P; Pålsson B; Andren-Sandberg A
Int J Pancreatol; 1991 May; 8(4):333-44. PubMed ID: 1791319
[TBL] [Abstract][Full Text] [Related]
35. TATI, TAT-2, and CRP as Prognostic Factors in Colorectal Cancer.
Björkman K; Kaprio T; Beilmann-Lehtonen I; Stenman UH; Böckelman C; Haglund C
Oncology; 2022; 100(1):22-30. PubMed ID: 34794144
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of TATI and CYFRA 21-1 in patients with head and neck squamous cell carcinoma.
Goumas PD; Mastronikolis NS; Mastorakou AN; Vassilakos PJ; Nikiforidis GC
ORL J Otorhinolaryngol Relat Spec; 1997; 59(2):106-14. PubMed ID: 9166881
[TBL] [Abstract][Full Text] [Related]
38. [Diagnostic value of serological tumor marker tests in patients with ovarian cancer].
Kobayashi H; Sumimoto K; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct; 41(10):1501-6. PubMed ID: 2573640
[TBL] [Abstract][Full Text] [Related]
39. A novel discriminant score based on tumor-associated trypsin inhibitor for accurate diagnosis of metastasis in patients with breast cancer.
El-mezayen HA; Metwally FM; Darwish H
Tumour Biol; 2014 Mar; 35(3):2759-67. PubMed ID: 24222329
[TBL] [Abstract][Full Text] [Related]
40. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids.
de Bruijn HW; ten Hoor KA; Boonstra H; Marrink J; Krans M; Aalders JG
Tumour Biol; 1993; 14(2):105-15. PubMed ID: 8392219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]